Bristol Myers Squibb today announced that the U.S. Food and Drug Administration (FDA) has approved Sotyktu® (deucravacitinib) for the treatment of adults with active psoriatic arthritis (PsA).1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results